Skip to the answer

Anifrolumab-fnia Injection Uses, Dosage, Side Effects and Interactions

Brand name
Saphnelo

Saphnelo is a brand of anifrolumab-fnia injection that comes as an injection.

Anifrolumab-fnia injection is a targeted biologic medicine used to treat moderate to severe systemic lupus erythematosus (SLE) in adults who are already on standard therapy.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Anifrolumab-fnia InjectionType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Anifrolumab-fnia Injection in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Saphnelo (anifrolumab-fnia) is a biologic for adults with moderate to severe systemic lupus erythematosus (SLE). It blocks the type I interferon receptor, a signaling switch that drives much of the inflammation in lupus. It is added to standard lupus treatment, not used instead of it, and has been on the U.S. market since about 2021 with no generic or biosimilar version yet. Most people tolerate it fairly well, and the side effects they notice most are colds, bronchitis and cough. The thing to watch for is infection, especially shingles (a painful, blistering rash on one side of the body), which can be severe on this drug.

Key Takeaways From the HelloPharmacist Team

  • Expect an IV infusion in a clinic every 4 weeks, or a weekly shot under the skin you give yourself at home.
  • Get your vaccines up to date before the first dose, and avoid live vaccines, such as the nasal flu spray, while on Saphnelo.
  • Call your prescriber promptly for fever, chills, a cough that will not quit or trouble breathing, since serious infections can develop on it.
  • Get emergency help for sudden swelling of the face, lips or throat, or trouble breathing, which are signs of a serious allergic reaction.

How we write and review this content: our editorial policy

Anifrolumab-fnia Injection by the Numbers

Strengths
2
in one form
Makers and packagers
1
Earliest FDA record
2021
Rank by Medicaid prescriptions
#955 of 1,682 drugs
More prescriptions than 43% of the 1,682 drugs we measure
10,185 prescriptions, Q1–Q4 2025

Patient Information Guide for Anifrolumab-fnia Injection

What It’s Used For

Anifrolumab-fnia injection is approved for one condition across its supported product, Saphnelo:

  • Saphnelo (intravenous or subcutaneous): Treatment of moderate to severe systemic lupus erythematosus (SLE) in adults who are already receiving standard therapy
  • Saphnelo is not recommended for patients with severe active lupus nephritis (kidney inflammation from lupus) or severe active central nervous system lupus — effectiveness in these situations has not been established

How It Works

Anifrolumab-fnia is a human monoclonal antibody — a precisely engineered protein — that locks onto a specific docking site on immune cells called the type I interferon receptor (IFNAR1). Type I interferons are immune signaling molecules that are overactive in most people with SLE, driving the inflammation that damages tissues and organs. By blocking this receptor and reducing the number of receptors available on the cell surface, Saphnelo turns down this inflammatory signal, quiets overactive immune responses, and helps normalize the immune cells that play a role in lupus flares.

Drug Class

Drug Class

  • Type I interferon Receptor Antagonist
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Type I interferon Receptor Antagonist

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Type I interferon Receptor Antagonists

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Anifrolumab-fnia Injection in the FDA’s index.

From our Patient Information GuideAnifrolumab-fnia is a human monoclonal antibody — a precisely engineered protein — that locks onto a specific docking site on immune cells called the type I interferon receptor (IFNAR1). Read How Anifrolumab-fnia Injection Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Anifrolumab-fnia Injection in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Monoclonal antibodies

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Saphnelo comes in two delivery options that your doctor will choose based on your situation.

  • Intravenous (IV) infusion: Administered by a healthcare provider over 30 minutes into a vein, once every 4 weeks. If a dose is missed, it should be given as soon as possible, with at least 14 days between infusions.
  • Subcutaneous injection (Saphnelo prefilled syringe or SAPHNELO PEN autoinjector): Injected under the skin once every week. Patients or caregivers can give this at home after proper training. If a dose is missed, take it as soon as remembered, maintaining at least 3 days between injections.

There are no food restrictions with either form. Follow your prescriber's exact instructions; do not change the route or schedule on your own.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Lupus (systemic lupus erythematosus)

Adults getting the medicine through a vein (IV) Usual dose 300 mg every 4 weeks
  • 300 mg, administered as an intravenous infusion over a 30-minute period every 4 weeks

Good to know

If a planned infusion is missed, give as soon as possible; keep a minimum interval of 14 days between infusions

IV means given into a vein (intravenous).

Adults getting the medicine as an injection under the skin Usual dose 120 mg once every week
  • 120 mg, administered as a subcutaneous injection once every week

Good to know

If a dose is missed, give as soon as remembered; keep a minimum interval of 3 days between subcutaneous injections

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects seen in clinical trials include:

Common side effects

  • Upper respiratory tract infections (including cold/nasopharyngitis)
  • Bronchitis
  • Herpes zoster (shingles)
  • Infusion-related reactions (headache, nausea, dizziness, fatigue)
  • Cough
  • Respiratory tract infections
  • Hypersensitivity reactions
  • Joint pain (arthralgia, reported post-marketing)
  • Infusion-related reactions — headache, nausea, vomiting, fatigue, dizziness (IV route)

When to get medical help

  • Signs of serious infection — high fever, chills, persistent cough, difficulty breathing — call your doctor right away
  • Signs of shingles — painful rash, blistering, burning or tingling on one side of the body — seek prompt medical care
  • Signs of a severe allergic reaction or anaphylaxis — throat tightening, difficulty swallowing or breathing, swelling of the face or lips — get emergency help immediately
  • Signs of angioedema (sudden swelling under the skin, especially around the mouth or throat) — seek emergency care
  • Any new or worsening infection that is not responding to treatment — contact your doctor so therapy can be reconsidered

Seek medical help right away for signs of a serious infection, a widespread shingles outbreak, or any symptoms of a severe allergic reaction such as swelling of the face or throat, difficulty breathing, or feeling faint.

Warnings and Precautions

  • Serious and fatal infections: Saphnelo suppresses the immune system and has been linked to serious infections, including COVID-19 and pneumonia. Shingles (herpes zoster) — including severe, multi-area cases — occurs significantly more often with Saphnelo than with placebo. Do not start Saphnelo during an active infection.
  • Severe allergic reactions: Anaphylaxis and angioedema have been reported. Saphnelo must be administered where these reactions can be treated immediately. Tell your doctor if you've ever had a severe allergic reaction to this drug — that is a contraindication.
  • Cancer risk: As with other immunosuppressants, there is a potential risk of malignancy. The full impact is not yet known. Your doctor will weigh this before prescribing.
  • Live vaccines: Do not receive live or live-attenuated vaccines while on Saphnelo. Get vaccinations up to date before starting treatment.
  • Other biologics: Saphnelo should not be combined with other biologic therapies — this has not been studied and is not recommended.

Interactions

Formal drug interaction studies have not been conducted with Saphnelo, but the label identifies important things to avoid or be careful with:

  • Live or live-attenuated vaccines: Must be avoided during treatment — Saphnelo's immune-suppressing effect can make live vaccines dangerous or ineffective
  • Other biologic therapies (including B-cell-targeted biologics): Not recommended in combination with Saphnelo — no safety data exist for this combination

Interactions Listed in the FDA-Approved Label

From the Anifrolumab-fnia Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Other drugs (formal drug interaction trials)
    What happensNo formal drug interaction trials have been conducted.
Read the label’s full interactions text

7 DRUG INTERACTIONS No formal drug interaction trials have been conducted.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Active infection: Do not start Saphnelo until any significant active infection is resolved or adequately treated
  • History of anaphylaxis to anifrolumab-fnia: This is a contraindication — Saphnelo must not be used
  • Chronic or recurrent infections: Discuss risks and benefits carefully with your doctor before starting
  • Known cancer risk factors or history of cancer: Your doctor should weigh the benefit-risk carefully
  • Pregnancy: Limited human data exist; monoclonal antibodies like anifrolumab-fnia can cross the placenta, especially in the third trimester, potentially exposing the fetus. A pregnancy registry is available — contact AstraZeneca at 1-877-693-9268.
  • Breastfeeding: It is unknown whether Saphnelo passes into human breast milk; discuss risks and benefits with your doctor
  • Children: Safety and effectiveness in pediatric patients have not been established
  • Adults 65 and older: Limited data are available; your doctor will assess appropriateness for your situation
  • Vaccinations: Update all vaccines before starting; live vaccines must be avoided during treatment

How Your Body Processes It

Anifrolumab-fnia is absorbed at about 73% when given by subcutaneous injection, and both the intravenous and subcutaneous routes reach steady-state blood levels in roughly 112 days (about 16 weeks). The drug is broken down by the body's normal protein-processing mechanisms — not by the liver — and it is cleared partly through a process driven by the very receptor it blocks (IFNAR1). After stopping Saphnelo, the drug becomes undetectable in the blood of most patients within about 16 weeks. No dose adjustments are needed based on age (18–70 years), sex, race, body weight, or mild-to-moderate kidney function changes.

Storage

Dispense in the original sealed carton with the enclosed Instructions for Use. Store SAPHNELO in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Supplements and Herbs That Interact With Anifrolumab-fnia Injection

From the licensed clinical database we use, rolled up per supplement, most serious first.

52 supplements and herbal products have documented interactions with Anifrolumab-fnia Injection in the licensed clinical database we use.

Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.

  • 51Moderate
  • 1Minor

See the other 44

Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Anifrolumab-fnia Injection: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Anifrolumab-fnia Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is Saphnelo and why has my doctor prescribed it for my lupus?

Saphnelo is a biologic medicine specifically designed for moderate to severe systemic lupus erythematosus, or SLE. It works by blocking a signaling pathway that's overactive in most people with lupus — the type I interferon pathway — which helps calm the immune system's attack on your own body. It's meant to be used alongside your existing lupus treatments, not to replace them. Your doctor chose it because standard therapy alone wasn't controlling your lupus well enough.

How will I actually receive this medication — will I have to go to a clinic every time?

There are two options. One is an IV infusion given at a clinic or infusion center by a healthcare provider, once every four weeks — each session takes about 30 minutes. The other is a once-weekly injection under the skin that you can do at home yourself, using either a prefilled syringe or an autoinjector pen called the SAPHNELO PEN, after you've been trained. Your doctor will decide which route makes the most sense for you, and you can switch between them if needed with your doctor's guidance.

What side effects should I expect, and which ones mean I need to call someone right away?

The most common ones are respiratory infections like colds and bronchitis, cough, and infusion reactions such as headache, nausea, or dizziness if you're getting the IV version. Shingles is a notable risk — it happens more often with Saphnelo than without it. You should call your doctor right away if you develop a painful, blistering rash (which could be shingles), signs of a serious infection like high fever or trouble breathing, or any sudden swelling of the face, lips, or throat, which could signal a dangerous allergic reaction.

Are there any vaccines or other medications I need to avoid while on Saphnelo?

Yes — you should not receive any live or live-attenuated vaccines while you're on Saphnelo, because the drug suppresses part of your immune system and live vaccines could be unsafe. Make sure all your vaccinations are up to date before you start treatment. You should also avoid other biologic medications at the same time as Saphnelo, because that combination hasn't been studied and isn't recommended. Always tell any new doctor or pharmacist that you're on Saphnelo.

Is Saphnelo safe if I'm pregnant or thinking about getting pregnant?

This is an important conversation to have with your doctor. There isn't enough human data yet to know for certain how Saphnelo affects pregnancy, but like other antibody medications, it can cross the placenta — especially in the third trimester — meaning the baby could be exposed. At the same time, uncontrolled lupus itself poses real risks in pregnancy. There's a pregnancy registry to track outcomes, and your doctor or AstraZeneca can connect you with it. Don't stop or start any medication during pregnancy without talking to your doctor first.

What happens if I miss a dose?

It depends on which form you're taking. If you're getting the IV infusion and miss your scheduled appointment, get it as soon as possible — but make sure at least 14 days pass between infusions. If you're doing the weekly subcutaneous injection at home and forget a dose, take it as soon as you remember, then wait at least 3 days before your next one. After that, you can either start a new weekly schedule from that day or resume your usual day. If you're ever unsure, just call your doctor or pharmacist.

Is anifrolumab-fnia injection available over the counter?

No. Anifrolumab-fnia injection is a prescription medicine: every anifrolumab-fnia injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was anifrolumab-fnia injection first available?

The earliest FDA record we hold for anifrolumab-fnia injection is from 2021: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when anifrolumab-fnia injection was first used.

What is the brand name of anifrolumab-fnia injection?

Anifrolumab-fnia injection is the generic name. Its brand name is Saphnelo.

What is the generic name of Saphnelo?

The generic name of Saphnelo is anifrolumab-fnia injection. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is anifrolumab-fnia injection?

Anifrolumab-fnia injection belongs to the drug class Type I interferon Receptor Antagonist, its established pharmacologic class on the FDA label.

What strengths does anifrolumab-fnia injection come in?

Anifrolumab-fnia injection is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein, under the skin): 120 mg/0.8 mL and 300 mg/2 mL. A listing does not mean every pharmacy stocks every strength.

Where can I read the anifrolumab-fnia injection prescribing information (package insert)?

The full FDA-approved prescribing information for anifrolumab-fnia injection, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from AstraZeneca Pharmaceuticals LP's, revised Sep 25, 2026, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Anifrolumab-fnia Injection

Skip the scrolling. Ask in your own words and get an answer from Anifrolumab-fnia Injection’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Anifrolumab-fnia Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Anifrolumab-fnia Injection on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, usually within a day.
Detailed Data & References for Anifrolumab-fnia Injection Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Anifrolumab-fnia Injection Forms and Strengths (How It Comes)

Anifrolumab-fnia Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Anifrolumab-fnia Injection inactive ingredients by manufacturer.

Injection

Into a vein · Under the skin
Brands Saphnelo
How this form is used
What it may be used for
  • Saphnelo intravenous infusion is used to treat moderate to severe SLE in adults receiving standard therapy
  • Saphnelo subcutaneous injection is used to treat moderate to severe SLE in adults receiving standard therapy
  • Saphnelo is not recommended for severe active lupus nephritis or severe active central nervous system lupus, regardless of route
Important instructions
  • Saphnelo intravenous: given by a healthcare provider as a 30-minute infusion into a vein, once every 4 weeks
  • Saphnelo subcutaneous (prefilled syringe or SAPHNELO PEN autoinjector): injected under the skin once every week; patients may self-inject after training from a healthcare provider
  • Saphnelo subcutaneous injections go into the thigh, abdomen (avoiding 2 inches around the navel), or upper arm (if a caregiver or healthcare professional gives the shot); rotate injection sites
  • When switching between the intravenous and subcutaneous routes, follow your doctor's timing guidance — do not switch without instruction
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Anifrolumab-fnia Injection on the U.S. Market: Products, Makers and Brands

How Anifrolumab-fnia Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Anifrolumab-fnia Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2021. The one brand name in the directory today is Saphnelo; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
2
FDA-listed product records ⓘ
2021
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished injection, solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Anifrolumab-fnia Injection Is Used (Medicaid Data)

How many Anifrolumab-fnia Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

10,185
Medicaid prescriptions filled (Q1–Q4 2025)
$49.1M paid by Medicaid, before rebates

How commonly is Anifrolumab-fnia Injection prescribed? Of the 1,682 medications we measure, Anifrolumab-fnia Injection ranks #955 by Medicaid prescriptions — more than 43% of them.

Where Anifrolumab-fnia Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Anifrolumab-fnia Injection product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

2 ML anifrolumab-fnia 150 MG/ML Injection

10,185 Medicaid prescriptions (Q1–Q4 2025) 100% of Anifrolumab-fnia Injection prescriptions shown $49.1M paid by Medicaid, before rebates ≈ $4,824 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2565280

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 1 listed Anifrolumab-fnia Injection NDCs had Medicaid claims.

Compare Anifrolumab-fnia Injection Products

A representative set of FDA-listed product records for Anifrolumab-fnia Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
120 mg/0.8 mL Subcutaneous AstraZeneca Pharmaceuticals LP BLA View NDC →
300 mg/2 mL Intravenous AstraZeneca Pharmaceuticals LP BLA View NDC →

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Anifrolumab-fnia Injection NDCs →

Anifrolumab-fnia Injection Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Anifrolumab-fnia recalls since July 2021.

✅No Anifrolumab-fnia recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Anifrolumab-fnia Injection in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
3
Strengths
3
Forms in current FDA listings
3 of 3
In current FDA listings No current FDA listing
Ingredient (IN) Anifrolumab-fnia Injection RxCUI 2565265
  1. Dose form (SCDF) Auto-Injector RxCUI 2741468
    In current FDA listings
    Its strength (SCD)
  2. Dose form (SCDF) Injection RxCUI 2565279
    In current FDA listings
    Its strength (SCD)
  3. Dose form (SCDF) Prefilled Syringe RxCUI 2741476
    In current FDA listings
    Its strength (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Anifrolumab-fnia Injection Brand Names

Anifrolumab-fnia Injection has one brand name on record: Saphnelo. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Saphnelo

Who Makes Anifrolumab-fnia Injection: Manufacturers and Labelers

One company lists Anifrolumab-fnia Injection products with the FDA. By number of product records, the largest are AstraZeneca Pharmaceuticals LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

AstraZeneca Pharmaceuticals LP 2

Sources for This Anifrolumab-fnia Injection Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Sep 25, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Anifrolumab-fnia Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
2
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
AstraZeneca Pharmaceuticals LP
Linked label effective
Sep 25, 2026
Composite sections available
21
Linked SPL Set ID
d6203302-2128-41a7-b0b4-0e6c0704d4dc
Linked SPL Document ID
0f042188-8a78-4ed5-b2af-a5b1e75b5f25
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AstraZeneca Pharmaceuticals LP is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →